Ajinomoto Bio-Pharma Services and DNDi Partner to develop Critical Immunomodulator

▴ ajinomoto-biopharma-services-and-dndi-partners-for-critical-immunomodulator
Partners will develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic

Ajinomoto Bio-Pharma Service, a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a strategic supply partnership with the Drugs for Neglected Disease Initiative (DNDi), a collaborative, patients' needs-driven, non-profit drug research and development organization that is developing new treatments for neglected diseases, for the supply of a CpG oligonucleotide, as part of a combination therapy used in the treatment of cutaneous leishmaniasis infections. This project is supported by the Global Health Innovative Technology (GHIT) Fund.

As part of this partnership, Aji Bio-Pharma will manufacture CpG-D35, a class of CpG oligonucleotides, which provides strong immunostimulatory effects. CpG-D35 will be used to stimulate the innate immune response in patients as an adjunct to chemotherapies in treating complicated cutaneous leishmaniasis (CL) and post-kala-azar dermal leishmaniasis (PKDL), persisting parasitic infections causing severely disfiguring and stigmatizing skin lesions.

"We are excited to be able to collaborate on this oligonucleotide with DNDi and support them in their efforts to develop and supply this quality of life-improving therapeutic for people with leishmaniasis," said Noriyasu Kataoka, Quality Manager & President, Ajinomoto Bio-Pharma Services Osaka. "We are pleased to be a trusted and innovative partner to our client while reinforcing our dedication in improving the health of humankind."

Over one billion people are at risk of leishmaniasis worldwide, which is transmitted by sandfly bites. Cutaneous leishmaniasis is the most common presentation, with about one million new cases annually. Post-kala-azar dermal leishmaniasis is a complication of visceral leishmaniasis, which can appear months or years after completing treatment.

"We are very pleased to be partnering with Ajinomoto Bio-Pharma Services for the supply of promising new therapeutic for the treatment of cutaneous leishmaniasis," said Dr Byron Arana, Head of Cutaneous Leishmaniasis Programme at DNDi. "With this partnership, we continue our goal to develop and provide safe and effective cutaneous leishmaniasis therapeutics."

Tags : #AjinimotoBiopharma #Dndi #dndi #NeglectedDiseaseInitiative #LatestPharmaNewsUpdateSep30

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Daily Covid-19 cases in US will hit six digits soon, warns expertsOctober 24, 2020
ICMR backed Covaxin could be ready by June 2021 ; Bharat BiotechOctober 24, 2020
Sewage signals early warning of coronavirus outbreaksOctober 24, 2020
U.S. sets single-day record for COVID-19 cases during new surgeOctober 24, 2020
Expert finds limited effectiveness of convalescent plasma for covid-19 patientsOctober 24, 2020
87 year old homeopathic doctor provides home visits to COVID-19 patients in Chandrapur district of MaharashtraOctober 24, 2020
Steroids boost survival of preterm babies in low-resource settings, new study findsOctober 24, 2020
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic CancerOctober 24, 2020
FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trialOctober 24, 2020
New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological CancersOctober 24, 2020
PMI Announces Medicago to Supply Up to 76 Million Doses of Its Plant-Derived COVID-19 Vaccine CandidateOctober 24, 2020
Gujarat records 1112 new cases of COVID-19 in last 24 hoursOctober 24, 2020
2377 COVID-19 patients recovered in Odisha in last 24 hoursOctober 24, 2020
Over 70 lakh people recovered from COVID-19 infection in country so farOctober 24, 2020
Health Minister Harsh Vardhan says next three months are crucial for country in fight against COVID-19October 24, 2020
Pfizer's Hospital Business section acquires Arixa Pharma October 24, 2020
India crosses the landmark of 10 crore total testsOctober 24, 2020
Bharat Biotech to conduct Phase 3 Trials Of Covaxin On 26,000 people across 25 sitesOctober 24, 2020
Catalent launches OptiGel DR, a delayed/enteric release Softgel October 24, 2020
Health Protection Campaign to be launched soon in ChhattisgarhOctober 24, 2020